Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Terminated 3Active not recruiting 3Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 5NIH 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Thymoma × Clear all
NCT04469725 2024-03-12

KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2 Terminated
95 enrolled
Thoracic

Thymoma

NCT01011439 2019-02-06

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Tiziana Life Sciences LTD

Phase 2 Terminated
72 enrolled 20 charts
Thoracic

Thymoma

NCT01301391 2019-02-06

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Tiziana Life Sciences LTD

Phase 2 Terminated
30 enrolled 19 charts
Thoracic

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡